

# Group sequential designs for Clinical Trials with multiple treatment arms

Susanne Urach, Martin Posch  
Cologne, June 26, 2015



This project has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement number FP HEALTH 2013-603160.

ASTERIX Project - <http://www.asterix-fp7.eu/>

# Objectives of multi-arm multi-stage trials

**Aim:** Comparison of several treatments to a common control

**Advantages:**

- less patients needed than for separate controlled clinical trials
- especially important for limited set of patients (rare diseases, children)
- larger number of patients are randomised to experimental treatments
- allows changes to be made during the trial using the trial data so far, e.g. stopping for efficacy or futility

**Objective:** Identify **all** treatments that are superior to control

**Objective:** Identify **at least one** treatment that is superior to control

→ **different kind of stopping rules!!**

## Design setup: group sequential Dunnett test

- control of the FamilyWise Error Rate (FWER) = 0.025
- comparison of two treatments to a control
- normal endpoints, variance known
- one sided tests:  $H_A : \mu_A - \mu_C \leq 0$  and  $H_B : \mu_B - \mu_C \leq 0$
- two stage group sequential trial: one interim analysis at  $\frac{N_{max}}{2}$
- power to reject at least one hypothesis = 0.8
- $Z_{A,i}, Z_{B,i}$  are the cumulative z-statistics at stage  $i=1,2$

## Classical group sequential Dunnett tests with “separate stopping”


## Classical group sequential Dunnett tests

**Objective:** Identify all treatments that are superior to control

**“separate stopping rule”:**

Treatment arms, for which a stopping boundary is crossed, stop.

E.g.:




→  $H_B$  is rejected at interim

→ A can go on and is tested again at the end

Magirr, Jaki, Whitehead (2012)

## Closed testing - sequentially rejective tests

**Local group sequential tests for  $H_A \cap H_B$  and  $H_A, H_B$  are needed!!!**



A hypothesis is rejected with FWER  $\alpha$  if the intersection hypothesis and the corresponding elementary hypothesis are rejected locally at level  $\alpha$ .

Xi, Tamhane (2015)

Maurer, Bretz (2013)

## Closed testing - sequentially rejective tests

$$H_A \cap H_B$$

Reject if  $\max(Z_{A,1}, Z_{B,1}) > u_1$  or  $\max(Z_{A,2}, Z_{B,2}) > u_2$

 $H_A$ 
 $H_B$ 

Reject if  $Z_{A,1} > v_1$  or  $Z_{A,2} > v_2$

Reject if  $Z_{B,1} > v_1$  or  $Z_{B,2} > v_2$

$u_1, u_2$ ...global boundaries

$v_1, v_2$ ...elementary boundaries

Koenig, Brannath, Bretz and Posch (2008)

## Group sequential Dunnett tests with “simultaneous stopping”




## Group sequential simultaneous stopping designs

**"simultaneous stopping rule":**

If at least one rejection boundary is crossed, the whole trial stops.

**Objective:** Identify at least one treatment that is superior to control

E.g.:  $H_B$  is rejected at interim



→ There is no second stage!

# Simultaneous versus Separate stopping

- **FWER** is controlled using the separate stopping design boundaries.
- **Lower expected sample size** compared to separate stopping designs.
- The **power to reject**
  - **any** null hypothesis is the **same** as for separate stopping designs.
  - **both** null hypotheses is **lower** than for separate stopping designs.

→ **Trade-off between ESS and conjunctive power!!!**

# Construction of efficient simultaneous stopping designs

- 1 Can one **relax the interim boundaries** when stopping simultaneously?
- 2 How large is the impact on **ESS and power** when stopping simultaneously or separately?
- 3 How to **optimize** the critical boundaries for either stopping rule?

## Question 1: Relaxation of interim boundaries?

### For simultaneous stopping:

- The boundaries  $u_1, u_2$  for the local test of  $H_A \cap H_B$  cannot be relaxed.
- The boundaries  $v_1, v_2$  for the local test of  $H_j$  can be relaxed.

### Intuitive explanation

If, e.g.,  $H_B$  is rejected at interim, but  $H_A$  not,  $H_A$  is no longer tested at the final analysis and not all  $\alpha$  is spent.

**It's possible to choose improved boundaries for the elementary tests.**

## Example: O'Brien Fleming boundaries

What changes when stopping simultaneously?

$$H_A \cap H_B$$

Reject if  $\max(Z_{A,1}, Z_{B,1}) > u_1$  or  $\max(Z_{A,2}, Z_{B,2}) > u_2$

$$u_1 = 3.14, u_2 = 2.22$$

 $H_A$ 
 $H_B$ 

Reject if  $Z_{A,1} > v_1$  or  $Z_{A,2} > v_2$

Reject if  $Z_{B,1} > v_1$  or  $Z_{B,2} > v_2$

$$v_1 = 2.80, v_2 = 1.98$$

$$v_1 = 2.80, v_2 = 1.98$$

# Example: O'Brien Fleming boundaries

$$H_A \cap H_B$$

Reject if  $\max(Z_{A,1}, Z_{B,1}) > u_1$  or  $\max(Z_{A,2}, Z_{B,2}) > u_2$

$$u_1 = 3.14, u_2 = 2.22$$

 $H_A$ 
 $H_B$ 


Reject if  $Z_{A,1} > v_1$  or  $Z_{A,2} > v_2$


Reject if  $Z_{B,1} > v_1$  or  $Z_{B,2} > v_2$

$$v_1 = 2.80, v_2 = 1.98$$

$$v_1 = 2.80, v_2 = 1.98$$

For simultaneous stopping there is no second stage test if one of the null hypotheses can already be rejected at interim.

FWER for simultaneous stopping if only  $H_A$  holds ( $\delta_A = 0$ )

FWER for simultaneous stopping if only  $H_A$  holds ( $\delta_A = 0$ )



# Example: O'Brien Fleming form of rejection boundaries

Improved boundary at interim for simultaneous stopping:

$$H_A \cap H_B$$

Reject if  $\max(Z_{A,1}, Z_{B,1}) > u_1$  or  $\max(Z_{A,2}, Z_{B,2}) > u_2$

$$u_1 = 3.14, u_2 = 2.22$$

$H_A$

$H_B$

Reject if  $Z_{A,1} > v_1$  or  $Z_{A,2} > v_2$

Reject if  $Z_{B,1} > v_1$  or  $Z_{B,2} > v_2$

$$v'_1 = 2.08, v_2 = 1.98$$

$$v'_1 = 2.08, v_2 = 1.98$$

For simultaneous stopping there is no second stage test if one of the null hypotheses can already be rejected at interim.

## Question 2: Impact on ESS and power?

global boundaries	$u_1 = 3.14, u_2 = 2.22$		
local $\alpha$ for test of $H_A \cap H_B$	$\alpha = 0.025$		
	separate stopping rule	simultaneous stopping rule	improved simultan.
local $\alpha$ for test of $H_j$	0.025	0.019	0.025
interim boundary $v_1$	2.80	2.80	2.08
final boundary $v_2$	1.98	1.98	1.98

## Question 2: Impact on ESS and power?

global boundaries	$u_1 = 3.14, u_2 = 2.22$		
local $\alpha$ for test of $H_A \cap H_B$	$\alpha = 0.025$		
	separate stopping rule	simultaneous stopping rule	improved simultan.
local $\alpha$ for test of $H_j$	0.025	0.019	0.025
interim boundary $v_1$	2.80	2.80	2.08
final boundary $v_2$	1.98	1.98	1.98
disj. power	0.8	0.8	0.8
N	162	162	162

## Question 2: Impact on ESS and power?

global boundaries	$u_1 = 3.14, u_2 = 2.22$		
local $\alpha$ for test of $H_A \cap H_B$	$\alpha = 0.025$		
	separate stopping rule	simultaneous stopping rule	improved simultan.
local $\alpha$ for test of $H_j$	0.025	0.019	0.025
interim boundary $v_1$	2.80	2.80	2.08
final boundary $v_2$	1.98	1.98	1.98
disj. power	0.8	0.8	0.8
N for $\delta_A = \delta_B = 0.5$	162	162	162
ESS for $\delta_A = \delta_B = 0.5$	154	149	149
conj. power for $\delta_A = \delta_B = 0.5$	0.59	0.50	0.56

## Optimized multi-arm multi-stage designs

# Optimal designs

Scenario	“Separate stopping”	“Simultaneous stopping”	“Improved simult. stopping”
<b>Boundaries</b>	classical group sequential	classical group sequential	improved group sequential
<b>Stopping rule</b>	separate stopping rule	simultaneous stopping rule	simultaneous stopping rule

# Optimal designs

Scenario	“Separate stopping”	“Simultaneous stopping”	“Improved simult. stopping”
<b>Boundaries</b>	classical group sequential	classical group sequential	improved group sequential
<b>Stopping rule</b>	separate stopping rule	simultaneous stopping rule	simultaneous stopping rule
$N_{max}$	chosen to achieve disjunctive power of 0.8		
<b>Obj. function optimize</b> $u_1, u_2$	minimize ESS under certain parameter configuration		


## Optimal designs

Scenario	“Separate stopping”	“Simultaneous stopping”	“Improved simult. stopping”
<b>Boundaries</b>	classical group sequential	classical group sequential	improved group sequential
<b>Stopping rule</b>	separate stopping rule	simultaneous stopping rule	simultaneous stopping rule
$N_{max}$	chosen to achieve disjunctive power of 0.8		
<b>Obj. function optimize</b> $u_1, u_2$	minimize ESS under certain parameter configuration		
<b>Obj. function optimize</b> $v_1, v_2$	minimize ESS	maximize conjunctive power	




# Power to reject both null hypotheses

Power to reject at least one hypothesis = 0.8



# Optimal expected sample size (ESS)



**Remarks:** Percentual reduction gets bigger, but stays between 5 and 12%

# Summary

- The **optimal design** depends on the objective:
  - Reject **all** hypotheses
  - Reject **at least one** hypothesis
- **Simultaneous stopping compared to separate stopping** leads to
  - lower expected sample size
  - the same power to reject any hypothesis
  - lower power to reject both hypotheses


**Improved boundaries** can be used to rescue some of the power to reject both null hypotheses.

- **Limitation:** If improved boundaries are used, the simultaneous stopping rule must be adhered to!
- **Extensions:**
  - unknown variance: t-test: p-value approach
  - more treatment arms, stopping for futility
  - optimal choice of first stage sample size/allocation ratio


## References

- Thall et al. (1989): one treatment continues, futility stopping, two stages, power comparisons under LFC
- Follmann et al. (1994): Pocock and OBF MAMS designs, Dunnett and Tukey generalisations, several stages
- Stallard & Todd (2003): only one treatment is taken forward, several stages, power comparisons
- Stallard & Friede (2008): stagewise prespecified number of treatments
- **Magirr, Jaki, Whitehead (2012)**: FWER of generalised Dunnett
- Koenig, Brannath, Bretz (2008): closure principle for Dunnett test, adaptive Dunnett test
- **Magirr, Stallard, Jaki (2014)**: Flexible sequential designs
- Di Scala & Glimm (2011): Time to event endpoints
- **Wason & Jaki (2012)**: Optimal MAMS designs
- **Tamhane & Xi (2013)**: multiple hypotheses and closure principle
- Maurer & Bretz (2013): Multiple testing using graphical approaches


FWER inflation when  $u_1^* = z_{1-\alpha} = 1.96$



# Difference in expected sample size: OBF design



# Difference in conjunctive power: OBF design



## Unknown variance: Extension to the t test

- p-value approach = quantile substitution (Pocock (1977)):**  
 z-score boundaries are converted to p-value boundaries and then converted to t-score boundaries:

$$u'_i = T_{2n_i-2}(\Phi^{-1}(u_i))$$

- for known variance:** sample size per arm per stage  $n$  of **8** for a power to reject at least one of 0.8 at  $\delta_A = \delta_B = 1$

(separate: ESS=32/power=0.61; improved simultaneous: ESS=30/power=0.51)

Simulation of t-statistics for p-value approach ( $\delta_A = \delta_B = 1$ )					
Design	n	$\alpha$	power at least one	power both	ESS
separate	8	0.0260	0.80	0.56	34
separate	10	0.0258	0.89	0.70	43
imp. sim.	8	0.0260	0.79	0.49	32
imp. sim.	10	0.0258	0.88	0.61	39



# Optimal boundaries

$\delta_A = 0.5, \delta_B = 0.5$			
Design	separate	simultaneous	improved simult.
$u_1$	2.64	2.48	2.48
$u_2$	2.29	2.37	2.37
$v_1$	2.09	2.16	2.05
$v_2$	2.29	2.20	1.97
conj. power	0.51	0.44	0.51
ESS	147	138	138